Skip to Main Content

++

Chapter 19. Dementia-Related Disorders Medication Therapy Management Data Set

++
++
++

Which of the following is the most important component of an initial MTM interview with a patient or caregiver regarding dementia?

++
++
++

a. Dedicate sufficient time for the visit

++
++

b. After the interview, ask the patient or caregiver, "Do you have any questions?"

++
++

c. Avoid discussing any sensitive issues such as inevitable decline, psychiatric complications (eg, depression, anxiety), or family support

++
++

d. Do not focus on their educational or health literacy status, since the MTM form is going to the primary physician

++
++
++

When performing a patient assessment it is crucial to:

++
++
++

a. Refer the patient to an assisted-living facility, despite his or her level of functioning

++
++

b. Review the current medication profile and ask about over-the-counter products and neutraceuticals

++
++

c. Avoid using any scales or inventories, since their use is limited in patients with dementia

++
++

d. Stay emotionless and focus on obtaining a detailed patient history

++
++
++

Which of the following is considered a therapeutic failure that may warrant a change in cognitive medications (eg, donepezil, galantamine)?

++
++
++

a. No change from baseline in the MMSE scores

++
++

b. A decrease from baseline in the MMSE by 1 to 2 points in a year

++
++

c. A decrease from baseline in the MMSE by 5 points in a year

++
++

d. Loose stools during the first 3 days of cholinesterase inhibitor therapy

++
++
++

Which of the following statements demonstrates proper use of living room language?

++
++
++

a. You have Alzheimer's disease. This is a neurocognitive disorder that will cause a deterioration of your cognitive abilities over time.

++
++

b. You have Alzheimer's disease. This is a disease that affects your memory and the ability to take care of yourself over time.

++
++

c. You have Alzheimer's disease. Pharmacologic treatment options include cholinesterase inhibitors and N-methyl-D-aspartate inhibitors, which work by regulating your neurotransmitters.

++
++

d. You have Alzheimer's disease. This is a cognitive disease, which can cause psychiatric conditions such as anhedonia, alogia, psychosis, and overall deterioration of your activities of daily life.

++
++
++

GR is a 75-year-old male who was recently diagnosed with Alzheimer's disease. His ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.